Quest Diagnostics (DGX): financials, SEC filings and peers
Quest Diagnostics (DGX) is a health care services company in the Health Care sector of the S&P 500, headquartered in Secaucus, New Jersey.
It was founded in 1967 and joined the S&P 500 on December 12, 2002.
Its fiscal year ends in December, and its shares trade on the NYSE.
In its SEC filings it is classified as “Services-Medical Laboratories”.
Quest Diagnostics at a glance
- Revenue (12 months)
- $11.8B
- Revenue growth
- +9.1%
- Operating margin
- 14.6%
- Net income (12 months)
- $1.1B
- Free cash flow (12 months)
- $1.4B
- Cash
- $797M
- Debt
- $5.5B
- Diluted EPS (12 months)
- $10.04
Twelve months to September 30, 2026, from the 10-Q filed October 23, 2026.
Latest twelve months
Over the twelve months to September 30, 2026, Quest Diagnostics reported revenue of $11.8 billion, up 9.1% from a year earlier.
Its operating margin was 14.6%: for every $100 of sales, about $15 was left as operating profit.
Net income was $1.1 billion (9.5% of revenue), 16.5% higher than a year earlier.
Operating cash flow was $2.0 billion and capital spending $576 million, leaving free cash flow of $1.4 billion (11.6% of revenue).
At the end of the period it held $797 million in cash and $5.5 billion in debt, a net debt position of $4.8 billion.
Five-year trend
- Revenue went from $9.4 billion in fiscal 2020 to $11.0 billion in fiscal 2025, about 3.2% a year.
- Operating margin narrowed from 20.9% to 14.1% over the same years.
- Free cash flow was positive in each of the last 6 fiscal years.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $10.8B | $9.9B | $9.3B | $9.9B | $11.0B |
| Revenue growth | 14.3% | -8.4% | -6.4% | 6.7% | 11.8% |
| Operating margin | 22.1% | 14.4% | 13.6% | 13.6% | 14.1% |
| Net income | $2.0B | $946M | $854M | $871M | $992M |
| Free cash flow | $1.8B | $1.3B | $864M | $909M | $1.4B |
| Diluted EPS | $15.55 | $7.97 | $7.49 | $7.69 | $8.75 |
Fiscal years as reported in Quest Diagnostics’s 10-K filings. Free cash flow is operating cash flow minus capital spending.
Recent SEC filings
- 10-Q filed October 23, 2026 — quarterly report
- 8-K filed October 22, 2026 — Other event
- 8-K filed October 22, 2026 — Earnings results
- 8-K filed October 6, 2026 — Executive or director change
- 10-Q filed July 23, 2026 — quarterly report
- 8-K filed July 23, 2026 — Earnings results
- 8-K filed May 21, 2026 — Shareholder vote results
- 8-K filed May 8, 2026 — Material agreement
Companies like Quest Diagnostics
Other S&P 500 companies in Health Care Services:
- CICignaBloomfield, Connecticut
- CVSCVS HealthWoonsocket, Rhode Island
- DVADaVitaDenver, Colorado
- LHLabcorpBurlington, North Carolina
More from Health Care
Questions about Quest Diagnostics
Is Quest Diagnostics's revenue growing?
Yes. Revenue for the twelve months to September 30, 2026 was $11.8 billion, up 9.1% from a year earlier, according to its SEC filings.
Is Quest Diagnostics profitable?
Yes. It earned $1.1 billion in net income over the twelve months to September 30, 2026, a net margin of 9.5%.
Does Quest Diagnostics have more cash or more debt?
At September 30, 2026 it had $797 million in cash and $5.5 billion in debt, so more debt than cash.
When did Quest Diagnostics last file financial results?
Its latest quarterly report (10-Q) was filed with the SEC on October 23, 2026.
Which companies are similar to Quest Diagnostics?
In the S&P 500, Quest Diagnostics is grouped in Health Care Services within the Health Care sector. Cigna (CI), CVS Health (CVS), DaVita (DVA), Labcorp (LH) are in the same group.
Understand the numbers
Source: Quest Diagnostics’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved November 11, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.